Altamira Therapeutics Ltd. (CYTOF)

Altamira Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	3.21	3.12	3.4	3.67	2.63	3.95
Research & Development	3.86	3.04	2.22	1.67	2.83	3.3
Other Operating Expenses	-0.23	-0.24	-0.01	0	-0.18	0.01
Operating Expenses	6.85	5.92	5.62	5.34	5.28	7.26
Operating Income	-6.85	-5.92	-5.62	-5.34	-5.28	-7.26
Interest Expense	-0.58	-1.03	-0.9	-0.01	-0.14	-0.03
Interest & Investment Income	0.31	0.3	0.11	0.03	0	0.02
Earnings From Equity Investments	-0.28	-0.04	-	-	-	-
Currency Exchange Gain (Loss)	-0.55	-0.45	-0.31	0.05	-0.33	-0.22
Other Non Operating Income (Expenses)	0.04	-0.17	0.45	0.01	-2.47	0.66
EBT Excluding Unusual Items	-7.91	-7.3	-6.26	-5.28	-8.22	-6.83
Asset Writedown	-	-	-12.4	-1.53	-	-
Other Unusual Items	0	0.03	-	-	-	-
Pretax Income	-7.91	-7.27	-18.66	-6.81	-8.22	-6.83
Income Tax Expense	-	-	-0.01	-0.12	-0.02	-0.19
Earnings From Continuing Operations	-7.91	-7.27	-18.65	-6.69	-8.2	-6.63
Earnings From Discontinued Operations	5.21	3.4	-7.88	-10.37	-	-
Net Income	-2.7	-3.87	-26.53	-17.06	-8.2	-6.63
Net Income to Common	-2.7	-3.87	-26.53	-17.06	-8.2	-6.63
Shares Outstanding (Basic)	1	0	0	0	0	-
Shares Outstanding (Diluted)	1	0	0	0	0	-
Shares Change (YoY)	1503.64%	978.83%	37.51%	120.26%	-	-
EPS (Basic)	-1.91	-7.88	-582.58	-515.11	-545.41	-
EPS (Diluted)	-1.91	-7.88	-582.58	-515.11	-545.41	-
Free Cash Flow	-7.58	-11.51	-8.68	-13.67	-4.84	-8.46
Free Cash Flow Per Share	-5.35	-23.43	-190.69	-412.87	-322.15	-
EBITDA	-	-	-5.57	-5.29	-5.26	-7.23
D&A For EBITDA	-	-	0.05	0.05	0.02	0.03
EBIT	-6.85	-5.92	-5.62	-5.34	-5.28	-7.26

Updated Sep 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.